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Background  :  Patients  with  diabetic  nephropathy  (DN)  and  coronary  artery  disease  (CAD)  represent  a  subset  of 
patients  with  high  cardiovascular  morbidity  and  mortality.  The  optimal  revascularization  strategy  using  either 
percutaneous  coronary  intervention  (PCI)  or  coronary  artery  bypass  grafting  (CABG)  remains  controversial.  The  purpose 
of  this  study  was  to  compare  the  clinical  outcomes  of  PCI  to  CABG  in  DN  patients  with  CAD.
Methods  :  The  clinical  and  angiographic  records  of  DN  patients  with  CAD  who  underwent  either  CABG  (n=52)  or 
PCI  (n=48)  were  retrospectively  analyzed.
Results  :  The  baseline  characteristics  were  similar  in  the  two  groups  except  for  the  severity  of  the  CAD.  At  30  days, 
the  death  rate  (PCI:  2.1%  vs.  CABG:  9.6%,  p=0.21)  and  major  adverse  cardiac  events  (MACE)  rate  (PCI:  2.1  %  vs. 
CABG:  9.6%,  p=0.21)  were  similar  in  comparisons  between  the  PCI  and  CABG  groups.  At  three  years,  the  death  rate 
(PCI:  18.8%  vs.  CABG:  19.2%,  p=0.94)  was  similar  between  the  PCI  and  CABG  groups  but  the  MACE  rate  (PCI:  47.9% 
vs.  CABG:  21.2%,  p=0.006)  was  higher  in  the  PCI  group  compared  to  the  CABG  group.  In  addition,  the  repeat 
revascularization  rate  was  higher  in  the  PCI  group  compared  to  the  CABG  group  (PCI:  12.5%  vs.  CABG:  1.9%,  p=0.046).
Conclusions  :  The  CABG  procedure  was  associated  with  a  lower  incidence  of  MACE  and  repeat  revascularization 
for  up  to  three  years  of  follow-up  in  DN  patients  with  CAD.  However,  the  overall  survival  rate  was  similar  in  the  CABG 
and  PCI  groups.  Therefore,  CABG  may  be  superior  to  PCI  with  regard  to  MACE  and  repeat  revascularization.
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INTRODUCTION
Coronary  artery  disease  (CAD)  is  highly  prevalent  in  patients 
with  diabetic  nephropathy  (DN)  and  the  incidence  of  DN  is 
increasing  worldwide.  Compared  to  nondiabetic  patients,  the 
postoperative  morbidity  and  mortality  are  higher  in  diabetic 
patients  after  coronary  artery  bypass  grafting  (CABG)  or 
percutaneous  coronary  intervention  (PCI)
1-3).  Furthermore,  the 
DN  patients  with  CAD  are  a  special  subset  of  diabetic  patients, 
who  are  known  to  be  at  a  higher  risk  compared  to  diabetic 
patients  without  nephropathy
4).  The  selection  of  the  most 
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patient  survival  in  DN  patients  with  CAD.  Angioplasty  for 
multivessel  CAD  has  become  increasingly  common  for  high-risk 
patients  with  comorbidities.  However,  a  major  drawback  of 
percutaneous  transluminal  coronary  angioplasty  is  the  abrupt 
vessel  closure  and  higher  restenosis  rates  compared  to  the 
CABG  procedure.  Technical  advances  such  as  the  use  of  a 
coronary  stent  have  decreased  the  restenosis  rates.  However, 
CABG  offers  the  advantage  of  a  more  complete  revasculariza-
tion  regardless  of  the  coronary  anatomy  at  the  time  of  the 
procedure.  Randomized
  trials  of  surgical  therapy  have  shown 
that  the  benefits  of  surgical
  revascularization  are  proportional  to 
the  amount  of  myocardium
  affected  by,  or  at  risk  for,  ischemic 
injury
5).  Although,  perioperative  morbidity  and  mortality,  duration 
of  hospital  stay  and  hospital  cost  is  higher  for  CABG,  several 
randomized  clinical  trials  including  the  BARI  (Bypass  Angioplasty 
Revascularization  Investigation)  have  suggested  that  CABG 
provided  superior  outcomes  in  the  subgroup  of  diabetic  patients 
due  to  better  long-term  patency  of  the  grafts  compared  to  PCI
6,7). 
Therefore,  contemporary  PCI  guidelines  emphasize  the 
long-term  survival  benefit  with  CABG  for  treatment  of  diabetics 
with  multivessel  CAD
8).  By  contrast,  survival  data  of  8818 
patients  derived  from  seven  registries  showed  a  long-term 
mortality  (5-12  years)  of  27.8%  in  patients  treated  by  PCI  and 
26.3%  in  patients  treated  by  CABG,  revealing  a  mortality  rate 
similar  for  the  two  groups
9).  The  reason  for  the  discrepancy 
between  the  subgroup  analysis  of  the  clinical  and  observational 
data  is  unclear,  even  though  it  is  well  known  that  CABG  patient 
registries  are  usually  much  more  clinically  compromised  than 
those  for  patients  undergoing  PCI.  Although  CABG  appeared  to 
provide  a  better  outcome  than  PCI,  most  of  the  findings  were 
obtained  by  subanalyses,  without  a  focus  on  DN  patients. 
The  purpose  of  this  study  was  to  compare  the  clinical 
outcomes  of  a  subset  of  diabetic  patients  with  high  cardiovas-
cular  risk,  DN  patients  with  CAD,  following  PCI  or  CABG. 
MATERIALS AND METHODS
Patients
All  clinical  records  and  catheterization  reports  of  type  2 
diabetic  patients  with  nephropathy  who  underwent  PCI  or  CABG 
at  our  institution  from  January  1,  1996  to  December  31,  2005 
were  retrospectively  analyzed  regarding  clinical  and  angio-
graphic  data.  Diabetic  nephropathy  was  defined  as  overt 
proteinuria  (proteinuria  >  500  mg/day)  or  a  glomerular  filtration 
rate  (GFR)  by  the  modified  MDRD  (Modification  of  Diet  in  Renal 
Disease)  equation
10)  of  less  than  60  mL/min/1.73  m
2.  The 
revascularization  strategy  was  determined  by  the  clinical  judg-
ment  of  the  cardiologists  and  cardiac  surgeons.  In  Brief,  PCI 
was  recommended  for  patients  with  single-  or  two-vessel 
disease  with  normal  or  slightly  depressed  global  left  ventricular 
function  and  for  those  with  lesions  anatomically  suitable  for  the 
procedure.  Whereas,  surgery  was  preferred  for  patients  with  left 
main  CAD  or  those  who  had  two-  or  three-vessel  disease  with 
impaired  global  left  ventricular  function  (left  ventricular  ejection 
fraction  <  45%)  or  other  lesions  unsuitable  for  catheter-  based 
procedures.  Repeat  revascularization  was  defined  as 
angiographic  ballooning  or  stenting  due  to  angiographic 
restenosis  at  the  site  of  previous  stent  deployment  or  graft,  the 
development  of  new  lesions  or  progression  of  untreated  lesions 
on  a  coronary  angiogram.
Pecutaneous  coronary  intervention  procedures
Coronary  angiography  was  performed  by  the  femoral 
approach  according  to  standard  techniques.  At  least  six 
standardized  projections  of  the  left  coronary  artery  and  two  of 
the  right  coronary  artery  were  obtained.  The  severity  of  the 
coronary  artery  disease  was  determined  visually  and  was 
classified  as  single,  double  or  triple  vessel  disease,  defined  by 
the  presence  of  hemodynamically  relevant  stenosis  (stenosis  > 
50%  of  the  luminal  diameter)  in  one  of  the  three  major  coronary 
vessels.  A  coronary  lesion  with  critical  stenosis  (stenosis  >  70% 
of  the  luminal  diameter)  was  selected  for  coronary  balloon 
angioplasty  and  stenting.  Balloon  angioplasty  and  commercially 
available  bare  metal  stent  implantation  were  performed 
according  to  standard  techniques.  The  stent  was  deployed  at 
the  culprit  lesion  by  inflating  a  balloon;  inflation  of  the  balloon 
expanded  the  stent.  After  the  implantation  of  the  stent,  the 
stented  area  was  often  dilated  further  by  standard  balloon 
angioplasty  techniques.  The  patients  received  500  mg  aspirin 
and  10,000  IU  of  heparin  before  the  procedure.  All  patients  were 
advised  to  take  lifelong  maintenance  aspirin  and  another 
antiplatelet  agent  (clopidogrel,  ticlopidine  or  cilostazol). 
Coronary  artery  bypass  grafting
The  bypass  surgery  followed  current  standard  techniques, 
preferably  with  a  left  internal  mammary  artery  for  revascu-
larization  of  the  left  anterior  descending  coronary  artery.  Standard 
operative  techniques  for  on-pump  CABG  for  patients  were  used, 
including  standard  cardiopulmonary  bypass,  moderate  hypothermia 
and  cold  potassium  cardioplegia  for  myocardial  protection. 
Off-pump  CABG  was  performed  using  mechanical  stabilization 
and  intravascular  shunting  of  the  target  coronary  arteries.
Composite  end  points
The  primary  clinical  end  points  were  major  adverse  cardiac 
events  (MACE)  including  death,  myocardial  infarction  and  repeat 
revascularization  at  30  days,  one  year  and  three  years.  The 
secondary  clinical  end  points  were  procedure  related  complica-
tions  including  stroke,  post-procedural  bleeding,  pneumonia, Ki  Sun  Bae,  et  al  :  PCI  versus  CABG  in  DM  nephropathy 141
PCI
(n=48)
CABG
(n=52)
p-value
Age  (years)
Male,  n  (%)
DM  duration  (years)
Hypertension,  n  (%)
Hypercholesterolemia,  n  (%)
Current  smoking,  n  (%)
RAS  blockade
CKD  by  eGFR
 
    Stage  2,  n  (%)
    Stage  3,  n  (%)
    Stage  4,  n  (%)
    Stage  5,  n  (%)
Previous  stroke,  n  (%)
Clinical  presentation
    Stable  angina,  n  (%)
    Unstable  angina,  n  (%)
    Myocardial  infarction,  n  (%)
Ejection  fraction  (%)
Previous  myocardial  infarction,  n  (%)
Vessel  territory  with  stenosis 
    Left  main  coronary  artery,  n  (%)
    Left  anterior  descending  artery,  n  (%)
    Left  circumflex  artery,  n  (%)
    Right  coronary  artery,  n  (%)
No.  of  vessel  territory  with  stenosis 
    One‐vessel  disease,  n  (%)
    Two‐vessel  disease,  n  (%)
        with  p-LAD  lesion
        without  p-LAD  lesion
    Three  vessel  disease,  n  (%)
No.  of  lesions  with  stenosis  ≥ 50%
64.0±9.8
32  (66.7%)
13.8±9.3
39  (81.3%)
23  (52.3%)
10  (20.8%)
42  (87.5%)
2  (4.2%)
29  (60.4%)
9  (18.8%)
8  (16.7)
8  (16.7%)
18  (37.5%)
17  (35.4%)
9  (19.1%)
53.0±15.1
4  (8.3%)
0  (0.0%)
41  (85.4%)
34  (70.8%)
31  (64.6%)
7  (14.6%)
25  (52.1%)
6  (12.5%)
19  (39.6%)
16  (33.3%)
3.6±1.6
65.6±8.8
31  (59.6%)
13.5±9.9
45  (86.5%)
14  (32.6%)
2  (3.8%)
42  (80.8%)
3  (5.8%)
35  (67.3%)
5  (9.6%)
9  (17.3%)
3  (5.8%)
16  (30.8%)
26  (50%)
20  (38.5%)
52.7±15.8
9  (17.3%)
11  (21.2%)
50  (96.2%)
46  (88.5%)
49  (94.2%)
4  (7.7%)
4  (7.7%)
2  (3.8%)
2  (3.8%)
44  (84.6%)
5.1±2.0
0.16
0.47
0.88
0.47
0.06
0.009
0.42
0.61
0.08
0.48
0.14
0.035
0.91
0.18
0.001
0.08
0.028
<0.001
<0.001
<0.001
PCI,  percutaneous  coronary  intervention;  CABG,  coronary  artery  bypass  grafting;  DM,  diabetes  mellitus;  RAS  blockade,  Use  of 
renin-angiotensin  system  blocker;  CKD,  chronic  kidney  disease;  eGFR,  glomerular  filtration  rate  estimated  by  modified  MDRD 
(Modification  of  Diet  in  Renal  Disease)  study  equation;  p-LAD,  proximal  left  anterior  descending  coronary  artery
Table  1.  Baseline  clinical  and  angiographic  characteristics 
renal  failure  requiring  dialysis,  and  atrial  flutter/atrial  fibrillation  at 
30  days. 
Statistical  analysis
Continuous  variables  were  expressed  as  mean±SD  and 
were  compared  in  the  CABG  and  PCI  groups  by  the  Student's 
t-test.  Categorical  variables  are  presented  as  percentages  and 
were  compared  by  the  chi-square  test.  For  MACE,  the  event 
time  was  the  number  of  days  from  the  initial  procedure  to  the 
first  event.  Time  to  death,  time  to  MACE  and  time  to  repeat 
revascularization  were  evaluated  at  30  days,  one  year  and  three 
years.  Survival  curves  were  generated  using  the  Kaplan-Meier 
method.  The  Log-rank  test  was  used  to  compare  survival  rates 
between  CABG  and  PCI  groups.  In  the  subgroup  analysis  of 
CABG,  according  to  type  of  surgery  or  graft,  the  Fisher's  exact 
test  was  used  to  obtain  the  correlation  of  off-pump  CABG  or 
internal  mammary  artery  with  MACE  or  death.  The  multivariable 
Cox  proportional  hazards  model  was  used  to  evaluate  baseline 
clinical  and  angiographic  characteristics  and  procedure-related 
variables  in  order  to  identify  independent  predictors  of  death 
and  MACE.  All  statistical  tests  were  two-tailed,  and  a 
significance  level  of  0.05  was  used  throughout.  Statistical 
analyses  were  performed  using  SPSS  version  12.0  (SPSS  Inc., 
Chicago,  Illinois,  USA).
RESULTS
Baseline  clinical  characteristics  and  revascularization 
data
The  pretreatment  demographic  and  clinical  characteristics 
and  risk  factors  in  the  PCI  and  CABG  groups  were  comparable, 
except  for  a  significantly  higher  number  of  smokers  in  the  PCI 
group  and  a  greater  number  of  patients  presenting  with 
myocardial  infarction  in  the  CABG  group  (Table  1).  The  CABG 
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PCI
No.  of  stents  implanted
Stent  type
    Bare-metal  stent,  n  (%)
Complete  revascularization  rate,  n  (%)
1.5±0.7
48  (100%)
12  (25.0%)
†
CABG 
Off-pump  CABG,  n  (%)
Grafts  per  patient
IMA  graft  to  LAD,  n  (%)
Complete  revascularization  rate,  n  (%)
23  (44.2%)
2.5±1.4
46  (88.5%)
32  (61.5%)
†
†Statistical  significance  between  the  PCI  and  CABG  groups, 
p-value  <0.001
PCI,  percutaneous  coronary  intervention;  CABG,  coronary  artery 
bypass  grafting;  IMA,  internal  mammary  artery;  LAD,  left 
anterior  descending  coronary  artery
Table  2.  Procedural  characteristics  for  PCI  and  CABG
CABG  group:  21.2%,  p=  0.001)  and  three  vessel  CAD  (PCI: 
33.3%  vs.  CABG:  84.6%,  p<0.001).  The  number  of  lesions  with 
a  greater  than  50%  stenosis  was  significantly  higher  in  CABG 
group  (PCI:  3.6±1.6  vs.  CABG:  5.1±2.0,  p<0.001)  (Table  1). 
Off-pump  CABG  was  performed  in  44.2%  of  the  patients  in 
the  CABG  group;  using  a  mean  of  2.5±1.4  grafts  per  patient. 
An  internal  mammary  artery  graft  to  the  left  anterior  descending 
artery  was  used  in  88.5%  of  CABG  patients  (Table  2).
Commercially  available  bare  metal  stents  were  used  in  the 
PCI  group.  The  number  of  lesions  revascularized  was 
significantly  smaller  in  the  PCI  group  than  in  the  CABG  group 
(PCI:  1.5±0.7  stents  vs.  CABG:  2.5±1.4  grafts,  p<0.001).  The 
complete  revascularization  rate  was  higher  in  the  CABG  group 
(PCI:  25.0%  versus  CABG:  61.5%,  p<0.001)  (Table  2).
30-day  clinical  outcomes 
In  the  CABG  group,  five  patients  died  (9.6%)  because  of 
cardiogenic  shock  (n=2),  hypovolemic  shock  due  to  postope-
rative  bleeding  (n=1),  respiratory  failure  due  to  a  possible  stroke 
(n=1),  and  sepsis  due  to  pneumonia  (n=1).  There  was  a 
spectrum  of  secondary  adverse  events  in  the  CABG  group: 
renal  failure  requiring  dialysis  (n=5),  atrial  fibrillation/atrial  flutter 
(n=2),  postoperative  lung  hemorrhage  (n=1),  and  pneumonia 
(n=1).  In  the  PCI  group,  one  patient  died  due  to  cardiogenic 
shock.  Secondary  adverse  events  in  the  PCI  group  included 
renal  failure  requiring  dialysis  (n=1)  and  postoperative 
pneumonia  (n=1).  The  MACE  and  death  rates  were  comparable 
in  the  CABG  and  PCI  groups  (p=0.21)  and  the  mean  hospital 
stay  was  significantly  shortened  in  the  PCI  group  (PCI:  10.2±
6.7  vs.  CABG:  18.7±7.7,  p<0.001)  (Table  3).
One-year  clinical  outcomes 
Between  31  days  and  one  year,  there  were  two  deaths  in  the 
PCI  group,  one  of  which  was  cardiac  related  (sudden  death 
possibly  due  to  stent  thrombosis).  Between  31  days  and  one 
year,  one  patient  in  the  PCI  group  had  a  myocardial  infarction. 
This  patient  had  an  acute  anterior  wall  myocardial  infarction  due 
to  thrombotic  occlusion  of  a  first  diagonal  branch  that  had 
previously  been  stented. 
The  MACE  and  death  rates  were  comparable  between  the 
CABG  and  PCI  groups  while  repeat  revascularization  rates  were 
significantly  higher  in  the  PCI  group  (PCI:  12.5%  vs.  CABG: 
1.9%,  p=0.046)  (Table  3,  Figure  1).
Three-year  clinical  outcomes 
Between  one  year  and  three  years,  there  were  six  deaths  in 
the  PCI  group  and  five  deaths  in  the  CABG  group.  The  causes 
of  death  assigned  to  the  PCI  group  were  as  follows:  acute 
myocardial  infarction  (two  patients),  cerebral  hemorrhage  (one 
patient),  aspiration  pneumonia  (one  patient),  renal  failure  (one 
patient),  and  cancer  (one  patient).  In  the  CABG  group,  the 
causes  of  death  were  acute  myocardial  infarction  (one  patient), 
sepsis  due  to  urinary  tract  infection  (two  patients)  and  sudden 
death  (one  patient). 
The  MACE  rate  was  lower  in  the  CABG  group  than  in  the 
PCI  group  (PCI:  47.9%  vs.  CABG:  21.2%,  p=0.006)  and  the 
death  rate  was  comparable  in  the  CABG  and  PCI  groups 
(p=0.94).  The  repeat  revascularization  rate  was  significantly 
lower  in  the  CABG  group  (PCI:  33.3%  vs.  CABG:  1.9%, 
p<0.001)  (Table  3,  Figure  2).
Subgroup  analysis  of  the  CABG  group  showed  that  the 
off-pump  CABG  and  the  on-pump  CABG  were  not  different  in 
the  death  (off-pump  CABG:  13%  vs.  on-pump  CABG:  25%, 
p=0.48)  and  MACE  rates  (off-pump  CABG:  17.4%  vs.  on-pump 
CABG:  25%,  p=0.73).  Internal  mammary  artery  grafts  provided 
greater  protection  from  death  (internal  mammary  artery  grafts: 
13.3%  vs.  saphenous  vein  grafts:  66.7%,  p=0.01,  odds 
ratio=0.077)  and  MACE  (internal  mammary  artery  grafts:  15.6% 
vs.  saphenous  vein  grafts:  66.7%,  p=0.015,  odds  ratio=0.092) 
than  the  saphenous  vein  grafts.
Predictors  of  MACE  and  death 
The  following  variables  were  entered  into  a  stepwise 
multivariable  Cox  proportional  hazards  model  for  MACE:  age, 
gender,  smoking  history,  GFR  by  the  MDRD  study  equation,  Ca 
X  P  product,  uric  acid,  ejection  fraction,  myocardial  infarction, 
prior  stroke,  peripheral  vascular  disease,  therapy  of  lipid- 
lowering  drug,  and  type  of  revascularization  (CABG  or  PCI).  The 
Cox  proportional  hazards  regression  model  demonstrated  that 
smoking  history  was  a  positive  independent  predictor  (hazard 
ratio:  HR,  1.030,  95%  CI,  1.006  to  1.055)  and  CABG  was  a 
negative  independent  predictor  (hazard  ratio:  HR,  0.189,  95%  CI, 
0.064  to  0.556)  of  MACE  (Table  4). 
The  Cox  proportional  hazard  regression  model  for  death Ki  Sun  Bae,  et  al  :  PCI  versus  CABG  in  DM  nephropathy 143
PCI
  (n=48)
CABG 
(n=52)
p-value
30  days
    MACE,  n  (%)
    Death,  n  (%)
    Myocardial  infarction,  n  (%)
    Repeat  revascularization,  n  (%)
    Stroke,  n  (%)
    Postoperative  bleeding,  n  (%)
    Postoperative  pneumonia,  n  (%)
    Renal  failure  requiring  dialysis,  n  (%)
    Atrial  fibrillation/Atrial  flutter,  n  (%)
    Length  of  in-hospital  stay  (days)
1  (2.1%)
1  (2.1%)
0  (0%)
0  (0%)
0  (0%)
0  (0%)
1  (2.1%)
1  (2.1%)
1  (2.1%)
10.2±6.7
5  (9.6%)
5  (9.6%)
0  (0%)
0  (0%)
0  (0%)
1  (1.9%)
1  (1.9%)
5  (9.6%)
2  (3.8%)
18.7±7.7
0.21
0.21
NA
NA
NA
0.33
0.95
0.11
0.61
<0.001
One  year
    MACE,  n  (%)
    Death,  n  (%)
    Myocardial  infarction,  n  (%)
    Repeat  revacularization,  n  (%)
9  (18.8%)
3  (6.3%)
1  (2.1%)
6  (12.5%)
6  (11.5%)
5  (9.6%)
0  (0%)
1  (1.9%)
0.37
0.53
NA
0.046
Three  years
    MACE,  n  (%)
    Death,  n  (%)
    Myocardial  infarction,  n  (%)
    Repeat  revacularization,  n  (%)
23  (47.9%)
9  (18.8%)
1  (2.1%)
16  (33.3%)
11  (21.2%)
10  (19.2%)
0  (0%)
1  (1.9%)
0.006
0.94
NA
<0.001
PCI,  percutaneous  coronary  intervention;  CABG,  coronary  artery  bypass  grafting;  MACE,  major  adverse  cardiac  event;  NA,  not  applicable
Table  3.  30-day,  one-year  and  three-year  clinical  outcomes
Figure  1.  Kaplan-Meier  estimates  of  overall  survival  (A),  MACE-free  survival  (B)  and  reintervention-free  survival  (C)  at  one  year.  Cum 
Survival,  cumulative  survival;  MACE,  major  adverse  cardiac  event;  CABG,  coronary  artery  bypass  grafting;  PCI,  percutaneous  coronary 
intervention.
demonstrated  that  myocardial  infarction  was  a  positive 
independent  predictor  (hazard  ratio:  HR,  5.671,  95%  CI,  1.230  to 
26.134)  and  higher  GFR  by  the  modified  MDRD  study  equation 
was  a  negative  independent  predictor  (hazard  ratio:  HR,  0.921, 
95%  CI,  0.876  to  0.969)  of  death  (Table  4).
DISCUSSION
This  retrospective,  observational  study  compared  the  clinical 
outcomes  between  PCI  and  CABG  in  DN  patients  with  CAD. 
The  overall  survival  was  similar  in  the  CABG  and  PCI  groups 
but  the  MACE  rates  and  incidence  of  repeat  revascularization 
were  significantly  higher  in  the  PCI  group  compared  to  the 
CABG  group  during  follow  up.  PCI  has  been  shown  to  be 
effective  in  reducing  clinical  symptoms  in  patients  with  CAD  and 
myocardial  ischemia.  PCI  may  be  the  preferred  strategy  of 
myocardial  revascularization  in  patients  with  serious  systemic 
illness  such  as  chronic  renal  failure  and  ESRD.  The  PCI 
procedures  are  less  invasive  than  CABG  and  therefore  are 
associated  with  less  physical  and  psychological  trauma. 
Compared  to  PCI,  CABG  is  more  invasive  and  the  perioperative 
mortality  and  morbidity  is  very  high  especially  in  chronic  renal 
failure  patients.  Furthermore,  a  longer  hospital  stay  following 
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hazard  ratio 95%  confidence  interval p-value
MACE
    CABG  vs  PCI
    Smoking  history  (PYs)
0.189
1.030
0.064-0.556
1.006-1.055
0.002
0.016
Death
    GFR  by  MDRD
    Presentation  of  MI
0.921
5.671
0.876-0.969
1.230-26.134
0.001
0.026
MACE,  major  adverse  cardiac  event;  CABG,  coronary  artery  bypass  grafting;  PCI,  percutaneous  coronary  intervention;  PYs,  pack‐
years;  GFR,  estimated  glomerular  filtration  rate;  MDRD,  modified  Modification  of  Diet  in  Renal  Disease  study  equation;  MI, 
myocardial  infarction
Table  4.  Independent  predictors  for  MACE  and  death
Figure  2.  Kaplan-Meier  estimates  of  total  survival  (A),  MACE-free  survival  (B)  and  reintervention-free  survival  (C)  at  three  years.  Cum 
Survival,  cumulative  survival;  MACE,  major  adverse  cardiac  event;  CABG,  coronary  artery  bypass  grafting;  PCI,  percutaneous  coronary 
intervention.
CABG  results  in  higher  hospital  costs.  It  has  been  generally 
accepted  that  CABG  is  the  preferred  revascularization  modality 
in  DN  patients  with  left  main  CAD  or  multivessel  disease  (three 
vessel  or  two  vessel  disease  including  proximal  left  anterior 
coronary  artery  lesion)  with  impaired  left  ventricular  function 
(ejection  fraction  <  0.35)  or  complex  lesions  (total  occlusion, 
calcified  lesions,  or  bifurcation  lesions)
11).  CABG  has  been 
associated  with  a  higher  incidence  of  significant  adverse 
postoperative  events.  Therefore,  in  patients  with  serious  illness 
such  as  chronic  renal  failure  and  ESRD,  PCI  can  be  an 
attractive  alternative  revascularization  strategy  to  CABG. 
However,  previously  reported  data  do  not  provide  support  for 
either  CABG  or  PCI  as  an  initial  strategy  for  diabetics  with 
multivessel  CAD  who  are  at  a  high  risk  for  adverse  outcomes 
with  CABG.
Our  study  on  patients  with  DN  showed  that  PCI  resulted  in 
outcomes  comparable  to  CABG  with  respect  to  survival  at  three 
years.  However,  the  repeat  revascularization  and  MACE  rates 
were  significantly  higher  in  the  PCI  group  than  in  the  CABG 
group  at  three  years  after  the  procedure.  The  anatomical 
patterns  of  CAD  in  the  diabetic  patients  may  influence  their 
prognosis  and  response  to  revascularization.  Previous  studies 
have  demonstrated  that  diabetic  patients  more  frequently  have 
left  main  coronary  artery  lesions,  multivessel  disease  and  diffuse 
CAD
12,13).  Our  study  results  demonstrated  that  the  CABG  group 
had  left  main  coronary  artery  lesions,  multivessel  disease,  and 
diffuse  CAD  more  frequently  than  the  PCI  group.  However,  the 
significantly  higher  complete  revascularization  rate  in  the  CABG 
group  (PCI:  25.0%  vs.  CABG:  61.5%,  p<0.001)  may  have 
influenced  the  clinical  outcomes.  Until  recently,  no  prospective 
trial  has  compared  CABG  with  PCI  in  DN  patients;  post  hoc 
analysis  of  trials  has  suggested  favorable  results  with  CABG  in 
diabetics.  The  Arterial  Revascularization  Therapy  Study  (ARTS) 
compared  the  relative  efficacy  of  CABG  and  multivessel  bare 
metal  stenting  in  diabetics  and  non-diabetics
14).  This  study 
showed  no  difference  in  mortality  between  PCI  and  CABG  in 
this  subset  of  diabetics  at  one  year.  However,  the  revasculari-
zation  rate  clinically  necessary  in  diabetics  treated  with  PCI  was 
twice  as  high  as  the  revascularization  rate  in  diabetics  treated 
with  CABG.  The  BARI  reported  that  for  patients  who  had 
diabetes,  and  symptomatic  multivessel  disease,  CABG  resulted 
in  an  improved  five  year  survival  rate  (81%)  compared  to  PTCA 
(65%).  However,  <  20%  of  patients  had  diabetes
6).  A  large 
observational  study  of  patients  with  multivessel  disease  reported 
that  CABG  was  associated  with  higher  adjusted  long-term 
survival  outcomes  than  PCI
15).  The  CABG  group  included 
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patients  with  diabetes  (33%),  while  25%  of  the  stented  group 
were  patients  with  diabetes.  After  the  subgroup  analysis  of  the 
patients  with  diabetes,  hazard  ratios  for  death  were  generally 
lower  after  CABG  than  after  PCI.  In  the  ARTS,  25%  of  patients 
had  chronic  kidney  disease  (CKD)  at  entry.  CABG  was 
associated  with  a  reduced  risk  for  revascularization  compared 
with  PCI
10).  In  a  recent  meta-analysis,  data  were  too  sparse  on 
renal  disease  patients  to  draw  any  definite  conclusion
16). 
However,  the  newly  published  Kidney  Disease  Outcomes 
Quality  Initiative  guidelines  emphasized  that  outcomes  in  dialysis 
patients  with  established  CAD  are  worse  than  outcomes  in  the 
general  population.  The  guidelines  support  CABG  as  the 
preferred  therapy  for  ESRD  patients  with  three-vessel  or  left 
main  CAD
17).  The  complete  revascularization  rate  with  PCI  in 
CKD  patients  ranges  from  only  25%  to  50%
18).  Patients  who 
have  CKD  and  undergo  PCI  were  more  likely  to  have  peripheral 
vascular  disease,  cerebrovascular  disease,  hypertension,  and 
diabetes  and  may  have  clinically  silent  CAD
19).  The  largest 
ESRD  population  studied  was  the  US  Renal  Data  System 
national  database  between  1978  and  1995.  In  nearly  7,000 
dialysis  patients  who  underwent  an  initial  PCI,  the  two-year 
survival  rate  was  roughly  50%.  Using  the  Cox  regression  model 
in  this  retrospective  comparison,  Herzog  et  al.  showed  that 
dialysis  patients  in  the  United  States  had  better  survival  rates 
after  CABG  than  after  PCI
20).  Le  Feuvre  et  al.  reported  a 
primary  success  rate  of  96%  in  21  dialysis  patients,  and  the 
need  for  repeat  intervention  was  similar  to  187  control 
participants  (30%  vs.  25%).  However,  at  two  years,  the  rate  of 
cardiac  death  was  15%,  compared  with  5%  in  the  control 
group
21).  Furthermore,  there  was  no  significant  difference  in  the 
mortality  rate  between  PCI  and  CABG  groups  if  they  had  the 
same  left  ventricular  function
22).  Our  study  group  was  unique 
with  regard  to  including  patients  with  diabetes  and  nephropathy. 
Patients  were  included  with  CKD  from  stage  3  to  stage  5  (95% 
of  whole  patients)  and  ESRD  patients  on  dialysis  (17%  of  whole 
patients).  Diabetes  mellitus  and  CKD  are  increasing  in  the 
general  population  and  many  of  these  patients  require  coronary 
revascularization  procedures  because  of  CAD.  Renal 
insufficiency  was  reported  as  an  independent  predictor  of  the 
one-year  mortality  after  PCI  in  a  previous  study
19).  Our  study 
showed  that  decreased  renal  function  was  an  independent 
predictor  of  the  three-year  mortality  after  PCI  or  CABG.
  Moreover,  our  study  showed  that  the  repeat  revasculari-
zation  rate  was  significantly  higher  in  the  PCI  group  compared 
to  the  CABG  group.  This  observation  may  result  from  the  fact 
that  CABG  is  not  associated  with  stent  restenosis  or  stent 
thrombosis,  and  that  arterial  grafts  may  protect  vessels  from 
atherosclerotic  progression  and  plaque  rupture
23, 24).  In  our 
study,  about  89%  of  patients  who  had  a  CABG  underwent  an 
internal  mammary  artery  graft.  Progressive  atherosclerosis  was 
responsible  for  repeat  revascularization  in  a  significant  number 
of  diabetic  patients
25, 26).  Progression  of  non-stented  lesions  was 
the  reason  for  revascularization  in  56%  of  patients  who  required 
repeat  revascularization  in  our  study.  Furthermore,  CABG 
provided  a  more  complete  revascularization  rate  than  PCI 
(CABG:  61.5%  vs.  PCI:  25.0%,  p<0.001).  If  one  could  effectively 
reduce  restenosis  in  PCI,  PCI  would  be  a  more  attractive 
treatment  modality  than  CABG.  Recently  published  data 
demonstrated  that  the  use  of  drug-eluting  stents  (DES) 
dramatically  reduced  the  incidence  of  restenosis
27).  However,  the 
outcomes  of  the  studies  using  DES  were  not  conclusive. 
Ben-Gal  et  al.  reported  that  the  midterm  clinical  outcome  of 
diabetic  patients  treated  surgically  was  better  than  that  of 
patients  undergoing  PCI  with  DES  despite  improved  results  of 
PCI  with  DES
28).  Our  study  did  not  include  patients  who 
received  a  PCI  with  DES  because  DES  was  only  recently 
introduced  at  our  hospital.  The  number  of  patients  who  received 
PCI  with  DES  is  very  small  so  it  is  impossible  to  obtain 
statistically  meaningful  results  by  comparing  clinical  outcomes  of 
PCI  with  the  bare  metal  stent  group  or  the  CABG  group  at 
three  years.  Our  results  showed  that  the  treatment  modalities 
(PCI  or  CABG)  affected  the  MACE  rate.  CABG  may  be  the 
preferred  treatment  modality  for  prevention  of  restenosis  and  for 
reducing  the  hospital  cost  for  reintervention.  However,  PCI  may 
be  preferred  for  revascularization  in  severely  ill  patients.
Study  limitations 
Our  study  has  several  important  limitations.  This  study  was  a 
single-center,  non-randomized,  uncontrolled  registry  that 
requires  validation  by  prospective  randomized  studies. 
Consequently,  systematic  comparison  of  long-term  outcome 
was  not  available.  The  rate  of  MACE  may  be  underestimated 
because  of  the  absence  of  follow-up  angiography  and  patient 
refusal  of  follow-up  angiography  and  the  possibility  of  silent 
ischemia.  As  only  periprocedural,  one-year  and  three-year 
outcomes  were  analyzed,  a  long-term  follow-up  study  will  be 
necessary  to  confirm  our  findings.  Van  Domburg  et  al.  reported 
that  a  slight  benefit,  up  to  ten  years,  in  favor  of  CABG  among 
a  diabetic  subgroup  was  comparable  to  the  results  in  the  BARI 
trial.  However,  after  ten  years,  both  survival  curves  converged
29). 
Another  important  limitation  is  that  comparative  studies  of  CABG 
and  PCI  can  rapidly  become  outdated  in  view  of  evolving 
medical  and  technological  procedural  improvements.  For 
example,  triple  therapy  with  antiplatelet  agents  (aspirin, 
clopidogrel  and  cilostazol),  adjunctive  use  of  glycoprotein  IIb/IIIa 
inhibitor,  new  antirestenosis  therapies  such  as  DES,  and 
coronary  brachytherapy  may  reduce  the  need  for  reintervention 
and  improve  long-term  outcome.  In  addition,  surgical  techniques 
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Conclusions
CABG  was  associated  with  a  lower  incidence  of  MACE  and 
repeat  revascularization  in  the  up  to  three-year  follow-up  of  DN 
patients  with  CAD.  However,  the  overall  survival  rate  was  similar 
in  the  CABG  and  PCI  groups.  CABG  may  be  superior  to  PCI 
during  this  timeframe  with  respect  to  MACE  and  the  repeat 
revascularization  rate.
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